SHINGRIX (GlaxoSmithKline Australia Pty Ltd)
Product name
SHINGRIX
Date registered
Evaluation commenced
Decision date
Approval time
91 (255 working days)
Active ingredients
recombinant Varicella Zoster Virus glycoprotein E antigen
Registration type
EOI
Indication
SHINGRIX (powder and suspension for injection) is now also indicated for the prevention of herpes zoster (HZ) and post-herpetic neuralgia use in adults 18 years of age or older at increased risk of HZ.